» Articles » PMID: 37623048

HIV-1 Low-Frequency Variants Identified in Antiretroviral-Naïve Subjects with Virologic Failure After 12 Months of Follow-Up in Panama

Overview
Journal Infect Dis Rep
Publisher MDPI
Date 2023 Aug 25
PMID 37623048
Authors
Affiliations
Soon will be listed here.
Abstract

Low-frequency mutations associated with drug resistance have been related to virologic failure in subjects with no history of pre-treatment and recent HIV diagnosis. In total, 78 antiretroviral treatment (ART)-naïve subjects with a recent HIV diagnosis were selected and followed by CD4+ T lymphocytes and viral load tests to detect virologic failure. We sequenced the basal samples retrospectively using next-generation sequencing (NGS), looking for low-frequency mutations that had not been detected before using the Sanger sequencing method (SSM) and describing the response to ART. Twenty-two subjects developed virologic failure (VF), and thirteen of them had at least one drug-resistance mutation associated with Reverse Transcriptase Inhibitors (RTI) and Protease Inhibitors (PIs) at frequency levels ≤ 1%, not detected previously in their basal genotyping test. No resistance mutations were observed to Integrase Strand Transfer Inhibitors (INSTIs). We identified a possible cause of VF in ART-naïve subjects with low-frequency mutations detected. To our knowledge, this is the first evaluation of pre-existing drug resistance for HIV-1 minority variants carried out on ART-naïve people living with HIV/AIDS (PLWHA) by analyzing the HIV-1 gene using NGS in the country.

Citing Articles

Genetic landscape for majority and minority HIV-1 drug resistance mutations in antiretroviral therapy naive patients in Accra, Ghana.

Appiah P, Gbassana G, Adusei-Poku M, Obeng B, Duedu K, Sagoe K Heliyon. 2024; 10(12):e33180.

PMID: 39022058 PMC: 11253264. DOI: 10.1016/j.heliyon.2024.e33180.

References
1.
Mbisa J, Ledesma J, Kirwan P, Bibby D, Manso C, Skingsley A . Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK. J Antimicrob Chemother. 2020; 75(11):3311-3318. PMC: 7566560. DOI: 10.1093/jac/dkaa309. View

2.
Murillo W, de Rivera I, Parham L, Jovel E, Palou E, Karlsson A . Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med. 2009; 11(2):95-103. DOI: 10.1111/j.1468-1293.2009.00747.x. View

3.
Garcia-Morales C, Tapia-Trejo D, Matias-Florentino M, Quiroz-Morales V, Davila-Conn V, Beristain-Barreda A . HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020. Pathogens. 2021; 10(12). PMC: 8708254. DOI: 10.3390/pathogens10121587. View

4.
Li J, Stella N, Choudhary M, Javed A, Rodriguez K, Ribaudo H . Impact of pre-existing drug resistance on risk of virological failure in South Africa. J Antimicrob Chemother. 2021; 76(6):1558-1563. PMC: 8599859. DOI: 10.1093/jac/dkab062. View

5.
Mendoza Y, Bello G, Castillo Mewa J, Martinez A, Gonzalez C, Garcia-Morales C . Molecular epidemiology of HIV-1 in Panama: origin of non-B subtypes in samples collected from 2007 to 2013. PLoS One. 2014; 9(1):e85153. PMC: 3890310. DOI: 10.1371/journal.pone.0085153. View